Terms ending in 2036
Every in-force patent on Kymab Limited's record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,567,399 | Antibodies and Immunocytokines In force · High confidence | Kymab Limited | In force | High confidence | |
| US 9,617,338 | Antibodies and Immunocytokines In force · High confidence | Kymab Limited | In force | High confidence | |
| US 9,957,323 | Anti-Icos Antibodies In force · High confidence | Kymab Limited | In force | High confidence | |
| US 10,604,576 | Antibodies and Immunocytokines In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,858,996 | Anti-Icos Antibodies In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,965,026 | ANTI-PD-L1 and IL-2 Cytokines In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,920,128 | Methods, Cells & Organisms In force · High confidence | Kymab Limited | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.